Expanding the Utility of Antisclerostin Therapy

Privately held company. Since its inception, it has been capitalized using convertible notes, non-dilutive grants, and equity.

OssiFi is developing best in class sclerostin small molecule inhibitors to take advantage of new opportunities to develop safer, more effective bone building therapies. 

Sign up to keep updated on OssiFi news.

OssiFi takes pride in finding the perfect match for our team. We have created a culture that resonates our innovation.